In most MS-associated<unk> , visual function spontaneously improves over 2–3 months, and there is evidence that corticosteroid treatment does not affect the long term outcome. However, for<unk>  that is not MS-associated (or atypical<unk>  the evidence is less clear and therefore the threshold for treatment with intravenous corticosteroids is lower. Intravenous corticosteroids also reduce the risk of developing MS in the following two years in patients with MRI lesions; but this effect disappears by the third year of follow up. Paradoxically, oral administration of corticosteroids in this situation may lead to more recurrent attacks than in non-treated patients (though oral steroids are generally prescribed after the intravenous course, to wean the patient off the medication). This effect of corticosteroids seems to be limited to<unk>  and has not been observed in other diseases treated with corticosteroids. A Cochrane Systematic Review studied the effect of corticosteroids for treating people with acute<unk> . Specific corticosteroids studied included intravenous and oral methylprednisone, and oral prednisone. The authors conclude that current evidence does not show a benefit of either intravenous or oral corticosteroids for rate of recovery of vision (in terms of visual acuity, contrast sensitivity, or visual fields). There are a number of reasons why this might be the case.
Optic neuritis
Far-sightedness
Anterior ischemic optic neuropathy
Ischemic optic neuropathy
Posterior ischemic optic neuropathy
Ocular ischemic syndrome
Optic neuropathy
Vitreoretinopathy